Delmar Pharmaceuticals

Cancer research company GBM and Ovarian cancers

Based in CA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $32K in lobbying spend across 4 quarterly filings, Delmar Pharmaceuticals is an active lobbying client. Their lobbying covers 1 issue area.

$32K
Total Spend
1
Years Active
1
Firms Hired
1
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$32K

Issues Lobbied

Pharmacy

Lobbying Firms

U.S. Government Relations Intl.

Lobbyists

Jeffrey Taylor

Government Agencies Targeted

These are the government entities that Delmar Pharmaceuticals disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATE
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy

Educate Congress on matters involving cancer research specifically GBM and ovarian cancers

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Jazz Pharmaceuticals, INC.
$11.5M total spend
Global Blood Therapeutics
$3.3M total spend
Ascendis Pharma, INC.
$3.0M total spend
Hims & Hers Health, INC.
$2.3M total spend
Dynavax Technologies
$2.3M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.